LONDON, June 5, 2017 /PRNewswire/ —
Genkyotex is a Euronext-listed company formed by the merger of Genticel and Genkyotex focused on NOX science and its application in fibrosis and other indications. The lead asset, GKT831, will start a Phase II trial in primary biliary cholangitis…
June 05, 2017 at 04:52PM
from
No comments:
Post a Comment